Tasly Pharmaceutical Pays $45 Million for Stake in New Century Pharma

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

October 5, 2013 -- Tianjin Tasly Pharma acquired a 45% stake in Henan New Century Pharmaceutical for 151 million RMB ($24.7 million). New Century is a TCM maker whose primary product is Xingnaojing injection, a treatment for stroke. The drug has a wide range of indications combined with minimal side effects. Xingnaojing injection is the second best-selling cerebral TCM product in China. Tasly’s portfolio already includes salvianolic acid injection, also a stroke treatment. More details....

Stock Symbol: (SHA: 600535)

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC